课题基金 / 基金详情

MAGIC - Magnetic Resonance Assessment of Gene Imaging Constructs

MAGIC - Magnetic Resonance Assessment of Gene Imaging Constructs
MAGIC - 基因成像构建体的磁共振评估
批准号:
7211047
负责人:
RALPH P. MASON
金额:
$15.7万
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-06-01 至 2009-05-31

项目摘要

项目成果

RALPH P. MASON的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): We will develop a novel approach to detecting transgene activity in tumors based on proton MRI of enzyme activated reporter molecules. Specifically, we will synthesize, evaluate, optimize, and apply novel agents to detect (3-galactosidase activity generated by the lacZ gene. Gene therapy holds great promise for treatment of cancer. However, major problems involve assessing delivery to target tissue, the uniformity (versus heterogeneity) of bio distribution and determining whether the genes are expressed. We propose a novel approach for evaluating gene expression using MRI. This research draws on foundations in optical detection of reporter genes, specifically P- galactosidase from the lacZ gene. Recently, 3,4-cyclohexenoesculetin-p-galactopyranoside, marketed commercially as S-Gal(tm), has been shown to generate an intense black color as a precipitate upon activation by p-gal in the presence of Fe3+ ions. This prompted us to consider the paramagnetic properties of the precipitate as a potential 1H MRI contrast agent. Preliminary studies have demonstrated feasibility and we now wish to translate and develop the concept to tumor cells for detection in vivo. Specific aim 1 will explore the utility of S-gal, with investigations to optimize and validate the technique. MRI parameters will be varied to maximize contrast with appropriate spatial and temporal resolution. Agent administration will be evaluated to maximize contrast and minimize toxicity. Specific aim 2 will focus on translation to tumors in living mice. MRI will be validated by comparison with optical methods in vivo and traditional methods such as histology and RT-PCR. Specific aim 3 focuses on the synthesis and development of alternate optimized substrates. We believe this approach can both become a valuable tool for detecting p-gal activity in vivo and serve as a proof of principle for a novel platform technology adaptable to other reporter genes and endogenous enzymes such as proteases.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Novel nanoparticles to stimulate therapeutic angiogenesis in peripheral arterial disease
  • 批准号:
    10462909
  • 项目类别:
  • 资助金额:
    $53.67万
  • 财政年份:
    2022
  • 负责人:
    RALPH P. MASON
  • 依托单位:
Novel nanoparticles to stimulate therapeutic angiogenesis in peripheral arterial disease
  • 批准号:
    10756875
  • 项目类别:
  • 资助金额:
    $5.97万
  • 财政年份:
    2022
  • 负责人:
    RALPH P. MASON
  • 依托单位:
Novel nanoparticles to stimulate therapeutic angiogenesis in peripheral arterial disease
  • 批准号:
    10616740
  • 项目类别:
  • 资助金额:
    $53.03万
  • 财政年份:
    2022
  • 负责人:
    RALPH P. MASON
  • 依托单位:
Vascular image-guided optimization of response (VIGOR) to therapy in kidney cancer
  • 批准号:
    10646312
  • 项目类别:
  • 资助金额:
    $48.08万
  • 财政年份:
    2020
  • 负责人:
    RALPH P. MASON
  • 依托单位: